{"entity":{"id":"rakuten-medical","kind":"company","name":"Rakuten Medical","aka":["Rakuten Medical, Inc."],"tldr":"Rakuten Medical is a United States-based biotechnology company running 3 late-stage cancer trials in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma.","summary":"Rakuten Medical, based in San Diego, the United States, is a biotechnology company. Rakuten Medical is a biotechnology company creating and bringing to market drugs and devices to treat cancers based on its Alluminox platform of photoimmunotherapy. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma. The largest, NCT06699212 (A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases), plans to enrol 412 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.rakuten-med.com"},{"label":"ClinicalTrials.gov: trials led by Rakuten Medical","url":"https://clinicaltrials.gov/search?lead=Rakuten%20Medical%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["head-and-neck","cutaneous-scc"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab-sarotalocan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06699212","nct03769506","nct04305795"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego","country":"US","companyType":"biotech","website":"https://www.rakuten-med.com","founded":2010,"stage":"private-large","investors":[],"funding":[]},"route":"/companies/rakuten-medical/","neighbours":{"cancer":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/"}],"trial":[{"id":"nct06699212","kind":"trial","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","route":"/trials/nct06699212/"},{"id":"nct04305795","kind":"trial","name":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","route":"/trials/nct04305795/"},{"id":"nct03769506","kind":"trial","name":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","route":"/trials/nct03769506/"}],"technology":[{"id":"photodynamic-therapy-lasers","kind":"technology","name":"Photodynamic therapy lasers and light sources","route":"/technologies/photodynamic-therapy-lasers/"}]}}